Methods for identifying compounds for treating diabetes mellitus
AssigneeBioCrine AB
InventorSuad Efendic
Life of this patent
Estimating the term…
Abstract
The invention is directed to methods for identifying candidate beta cell-sensitizing compounds comprising providing a pancreatic beta islet cell population derived from a diabetic subject, contacting the beta islet cell population with one or more somatostatin receptor 5-binding compounds, and identifying those somatostatin receptor 5-binding compounds that promote insulin secretion from the pancreatic beta islet cell population at a higher rate than from a control cell population. The invention is further directed to methods for treating type II diabetes comprising administering a beta cell-sensitizing compound identified by the first method of the invention to a diabetic patient in need of treatment.
Claims2
A method for identifying candidate pancreatic beta cell-sensitizing compounds comprising:
- (a) providing a pancreatic beta-islet cell population derived from a diabetic subject, wherein the pancreatic beta islet cell population comprises pancreatic beta islet cells expressing somatostatin receptor 5;
- (b) contacting the pancreatic beta-islet cell population with one or more somatostatin receptor 5-binding test compounds, wherein the contacting is performed at a glucose concentration of between 8 mM and 30 mM;
- and
- (c) identifying those somatostatin receptor 5-binding test compounds that promote insulin secretion from the pancreatic beta-islet cell population to a greater degree than from a control pancreatic beta-islet cell population from a normoglycemic subject, wherein such compounds are candidate pancreatic beta cell-sensitizing compounds.
Dependencies are inferred from the claim text.